Get all premium features to the best stock analysis tool

Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results

Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated in Q2 2026 Cash, cash equivalents, and investments of $61.0 million as of March 31, 2026; runway into second quarter of 2027 Live stockholder fireside chat scheduled for May 8, 2026 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.

Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors

Appointment strengthens Board's clinical development and regulatory expertise as Vaxart advances its oral vaccine platform

Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital

SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced that it has entered into a share purchase agreement (SPA) with Lincoln Park Capital Fund.

Hagens Berman Sobol Shapiro LLP and Scott+Scott Attorneys at Law LLP Announce a Class Action for All Vaxart Shareholders that May Include You, Even if You Participated in the Previous Partial Settlement with Vaxart

NEW YORK--(BUSINESS WIRE)--Hagens Berman Sobol Shapiro LLP & Scott+Scott Attorneys at Law LLP: UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA In re VAXART, INC. SECURITIES LITIGATION This Document Relates to: ALL ACTIONS Master Case No. 3:20-cv-05949-VC SUPPLEMENTAL SUMMARY NOTICE OF CLASS CERTIFICATION THIS SUPPLEMENTAL NOTICE PROVIDES ONLY LIMITED INFORMATION ABOUT THE CASE PLEASE VISIT WWW.VAXARTSECURITIESLITIGATION.COM FOR MORE INFORMATION The Court has certified this laws.